



Avila Therapeutics to Present at J.P. Morgan Healthcare Conference

BEDFORD, MA - January 3, 2012 - Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that Katrine Bosley, Avila's CEO, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT on Monday, January 9, 2012, at the Westin St. Francis, San Francisco.

About Avila Therapeutics™, Inc.

Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes. The company's product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on cancer, viral infection and autoimmune disease. Avila's most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. For additional information, please visit <http://www.avilatx.com>.

Media Contact:
Gina Nugent
The Yates Network
617-460-3579